ViiV
ViiV’s HIV drug Rukobia gets EC marketing authorisation
February 9, 2021Manufacturing and Production HIV, ViiV
The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …
ViiV gets EU approval for children’s HIV treatment
January 13, 2021Research and Development EU, HIV, ViiV
ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission for Tivicay (dolutegravir) 5mg dispersible …
ViiV Healthcare announces authorisation of Europe’s first long-acting HIV injection
December 21, 2020Sales and Marketing GlaxoSmithKline, HIV, ViiV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced the authorisation of Europe’s first complete long-acting …
ViiV Healthcare’s two drug HIV therapy beats Gilead’s three drug treatment in Phase 3 trial
July 10, 2019Research and Development AIDS, Dovato, GSK, Gilead, HIV, ViiV, pharma
Pfizer and GlaxoSmithKline’s HIV company, ViiV Healthcare, has said its two-drug combo Dovato (dolutegravir and lamuvidine) met its primary endpoint …
Clinical trial will test long acting HIV injection
May 10, 2019Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable
A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
Monthly injections offer similar efficacy to daily pills in HIV phase 3 trials
March 8, 2019Medical Communications ATLAS, GSK, HIV, ViiV, flair, injectable
A long acting, injectable two drug regimen developed by Pfizer and GSK joint venture ViiV Healthcare and J&J subsidiary Jannsen, …
Janssen says cabotegravir/rilpivirine combo matches three-drug HIV maintenance therapy
February 24, 2016Research and Development Janssen, ViiV
Janssen has announced 32-week data from an ongoing phase IIb study of an HIV regimen comprised of its rilpivirine and …
ViiV completes BMS HIV pipeline purchase
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs
December 18, 2015Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare
Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …
ViiV in late-stage HIV trial success
September 23, 2015Research and Development HIV, Triumeq, ViiV, virology
Switching patients to Triumeq, a once-daily combination treatment for HIV, is as effective as remaining on antiretroviral therapy in certain …
Otsuka, ViiV and AstraZeneca named in ABPI code complaints
May 26, 2015Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Otsuka, PMCPA, ViiV
A ‘senior male employee’ of Otsuka Pharmaceuticals “potentially brought the industry into disrepute” by plying a female healthcare professional with …
GSK launches new HIV research centre
May 11, 2015Research and Development, Sales and Marketing AIDS, GSK, HIV, UNC-Chapel Hill, ViiV, qura
GlaxoSmithKline is boosting its philanthropic efforts in R&D into HIV/AIDS by teaming up with academic researchers to launch a new …
Reputation gains from focussing on the patient
May 11, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HIV, Manuel Goncalves, Pfizer, ViiV
Since being spun-off from GSK and Pfizer, specialist HIV firm ViiV Healthcare has earned the best corporate reputation amongst patients …
Boardroom shuffles at GSK and Roche
May 8, 2015Medical Communications, Sales and Marketing GSK, Novartis, Roche, ViiV, changes, leadership
GlaxoSmithKline and Roche have announced the latest changes to its leadership teams as the companies regroup for the year ahead. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
